Patients lose up to 11.3% body weight on new oral GLP‑1, reshaping outlook for obesity treatment costs
Obesity pills edge toward double‑digit weight loss as big pharma races for a US$100bn market by the 2030s, according to CNBC.
That shift from injectables to oral drugs is emerging as a key theme for long‑term healthcare and pharma exposure.
Structure Therapeutics said its oral GLP‑1 pill aleniglipron produced about 11.3 percent weight loss after 36 weeks at a 120 mg dose in adults with obesity and at least one weight‑related comorbidity, in a mid‑stage trial of 230 participants, according to Reuters.
A separate study of higher doses showed up to 15.3 percent weight loss at 36 weeks on a 240 mg dose.
Bloomberg reported that the results put aleniglipron roughly in line with a rival pill from Eli Lilly, with about 10.4 percent of patients dropping out across all treatment arms due to side effects, similar to rates seen in Lilly’s pill trials.
Analysts flagged tolerability as the key risk: BMO Capital Markets analyst Evan Seigerman called the outcome a “near-homerun scenario,” according to Bloomberg, while others pointed to high nausea rates.
Citizens Bank analyst Jonathan Wolleben said “the tolerability profile looks ok, not great,” but argued that starting at a lower dose improves nausea, vomiting and discontinuations and “will translate to an improved Phase 3 profile.”
Market reaction was volatile but ultimately positive.
Bloomberg said Structure’s American depositary receipts fell in premarket trading before surging 30 percent, while Reuters reported that its shares were up more than 140 percent on the obesity data.
According to Reuters, Structure plans to begin late‑stage development by mid‑2026, after a meeting with the US Food and Drug Administration next year, and claims it can manufacture 6,000 metric tons of drug substance, “enough for 100 million patients per year,” according to CEO Raymond Stevens.
The backdrop is a rapidly expanding obesity drug category.
Reuters estimated the obesity treatment market could reach about US$150bn a year by the early 2030s, still dominated by injectable GLP‑1s such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
Reuters said both companies are expected to launch oral weight‑loss drugs next year, while Bloomberg noted they are awaiting US Food and Drug Administration approval for their pills.
Pfizer is rebuilding its obesity franchise through deals rather than in‑house pills alone.
CNBC reported that Pfizer struck an up to US$2.1bn licensing agreement with YaoPharma to develop and commercialize an oral GLP‑1 obesity drug, YP05002.
Under the deal, Pfizer will pay an up‑front US$150m, while YaoPharma, a unit of Shanghai Fosun Pharmaceutical, could receive up to US$1.94bn in milestones plus tiered royalties if the drug is approved, according to CNBC.
YP05002 is still in early‑stage development and remains years from market, but Pfizer plans to combine it with its own GIP‑targeting candidate in mid‑stage trials, mirroring the dual GLP‑1/GIP approach used in Eli Lilly’s Zepbound and diabetes drug Mounjaro, CNBC said.
The licensing deal follows Pfizer’s up to US$10bn acquisition of obesity biotech Metsera after what CNBC described as a fierce bidding war with Novo Nordisk.
In a note cited by CNBC, BMO’s Seigerman said “obesity diversification” looks promising in the short term for Pfizer and described the US$150m up‑front as “prudent capital conservation in light of the recent Metsera bidding war.”
Oral GLP‑1s are approaching injectable‑like efficacy, tolerability remains the main gating factor, and capital is concentrating around a few large players positioning for what CNBC said could be a roughly US$100bn weight‑loss drug market by the 2030s.
